Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.

Authors: Huang, Xuemei; Lewis, Mechelle M; Van Scoy, Lauren Jodi; De Jesus, Sol; Eslinger, Paul J; Arnold, Amy C; Miller, Amanda J; Fernandez-Mendoza, Julio; Snyder, Bethany; Harrington, William; Kong, Lan; Wang, Xi; Sun, Dongxiao; Delnomdedieu, Marielle; Duvvuri, Sridhar; Mahoney, Susan E; Gray, David L; Mailman, Richard B

Published In J Parkinsons Dis, (2020)

Abstract: BACKGROUND: Current drug treatments have little efficacy in advanced-to-end-stage Parkinson's disease (advPD), yet there are no reports of interventional trials in advPD. D1 dopamine agonists have the potential to provide benefit. OBJECTIVE: To determine the feasibility and safety of the selective D1/D5 dopamine partial agonist PF 06412562 in advPD. METHODS: A two-week, randomized, double blind, crossover phase Ib study in advPD patients compared standard-of-care (SoC) carbidopa/levodopa with PF 06412562. Each week, there was a Day 1 baseline evaluation with overnight levodopa washout, then treatment on Days 2 and 3 with either SoC or PF-06412562 (split dose 25 + 20 mg), followed by discharge on Day 4. Primary endpoints were safety and tolerability. Secondary endpoints were global clinical impression of change (GCI-C) rated by clinicians and caregivers. RESULTS: Eight advPD patients and their caregivers consented to participate and six were randomized (average disease duration: 22 y). None withdrew voluntarily. One participant with baseline Day 1 dehydration, pre-renal kidney injury, and autonomic dysfunction experienced symptomatic and serious hypotension after receiving PF-06412562 in Week 1 and was discontinued from the study. All other adverse events were rated mild (PF-06412562: n = 1, SoC: n = 0), moderate (PF-06412562: n = 1, SoC: n = 1), or severe but non-serious (PF-06412562: n = 3, SoC: n = 2). No clinically meaningful laboratory changes were observed. Among the five participants who completed the study, GCI-C favored PF-06412562 in two per clinicians' and four participants per caregivers' rating. CONCLUSION: PF-06412562 was tolerated in advPD patients. This study provides the feasibility for future safety and efficacy studies in this population with unmet needs.

PubMed ID: 32986682 Exiting the NIEHS site

MeSH Terms: Aged; Carbidopa/administration & dosage; Carbidopa/adverse effects; Carbidopa/pharmacology*; Cross-Over Studies; Dopamine Agonists/administration & dosage; Dopamine Agonists/adverse effects; Dopamine Agonists/pharmacology*; Double-Blind Method; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa/administration & dosage; Levodopa/adverse effects; Levodopa/pharmacology*; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease/drug therapy*; Receptors, Dopamine D1/agonists*; Receptors, Dopamine D5/agonists; Severity of Illness Index

Back
to Top